Retatrutide is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of Retatrutide is approximately 4-5 days. This means dosing once weekly is typical to maintain stable levels. The half-life directly affects how long Retatrutide remains active and influences optimal injection timing.
What Is the Half-Life of Retatrutide?
The half-life of Retatrutide is approximately 4-5 days. This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer Retatrutide to maintain therapeutic blood levels.
What Does Retatrutide's Half-Life Mean for Dosing?
With a half-life of approximately 4-5 days, Retatrutide requires dosing once weekly to maintain stable levels. The standard dosage of 4-12 mg weekly (maintenance after titration) via subcutaneous injection accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, Retatrutide reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For Retatrutide, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject Retatrutide?
Optimal timing depends on your research goals. A half-life of approximately 4-5 days means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (once weekly) for more stable levels throughout the day.
How Does Retatrutide's Half-Life Compare to Similar Peptides?
Retatrutide is a Triple hormone receptor agonist. Its half-life of approximately 4-5 days positions it with a longer duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your Retatrutide Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Retatrutide.
Open Calculator →Bottom Line: Retatrutide Half-Life and Dosing
Retatrutide has a half-life of approximately 4-5 days, supporting the standard protocol of 4-12 mg weekly (maintenance after titration) dosed once weekly over 48+ weeks (continuous therapy in trials).
Read our Retatrutide dosage guide for complete protocol details.
Complete Guide
Retatrutide : Benefits, Dosage, Side Effects & Research
Related Reading
- Retatrutide Dosage Guide
- Retatrutide Benefits
- Retatrutide Side Effects
- Retatrutide Stacking Guide
- Retatrutide Cycle Guide
- Retatrutide Research
Research-Grade Sourcing
If you're going to research Retatrutide, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Retatrutide?
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist. Novel synthetic peptide developed by Eli Lilly targeting GIP, GLP-1, AND glucagon receptors simultaneously. It is researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers.
What is the recommended Retatrutide dosage?
Common dosages: 4-12 mg weekly (maintenance after titration) administered once weekly via subcutaneous injection. Cycle length: 48+ weeks (continuous therapy in trials). Half-life: approximately 4-5 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of Retatrutide?
Gastrointestinal effects predominate: diarrhea, vomiting, constipation, nausea. Generally manageable and dose-dependent. Potential pancreatitis risk similar to GLP-1 agonists.
Is Retatrutide safe?
Retatrutide has shown a preliminary safety profile in research. Not FDA-approved as of March 2026. NDA filing expected late 2026-early 2027. All research should follow appropriate safety protocols.